Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) management guidelines suggest corticosteroids, IVIg, or plasma exchange as first-line treatments, with SCIg as a maintenance option.
• Limited literature exists on clinical experiences with SCIg for CIDP maintenance therapy.
• This study addresses practical aspects of transitioning to and optimizing SCIg therapy in CIDP patients.

Purpose of the Study:

• To outline practical approaches for SCIg transition and management optimization in CIDP.
• To consider varying dosing recommendations for SCIg in clinical practice.
• To provide guidance based on real-world patient cases.

Main Methods:

• A retrospective, multicenter study analyzing anonymized medical records from eight US centers.
• Inclusion of patients with CIDP who transitioned to SCIg.
• Analysis of clinical practices related to SCIg therapy management.

Main Results:

• Switching to SCIg was guided by patient-physician assessment, with 70% of switches due to preference for site of care.
• 63% of patients remained stable after transitioning to SCIg.
• Relapse-free rates were higher with equivalent or adjusted SCIg doses compared to baseline IVIg, and all relapsed patients restabilized upon dose increase.
• SCIg was well-tolerated, with 55% reporting better tolerance than IVIg.

Conclusions:

• Patient cases offer practical guidance for SCIg therapy in CIDP maintenance.
• Emphasizes individualized dosing, ongoing monitoring, and patient-centered engagement for optimizing long-term outcomes.
• Findings support informed clinical decision-making for SCIg use in CIDP.